compani updat chang price
 pt
note luke built world detail complex
sampl suppli demand model outsid least ive ever
seen model avail request pleas email us
debat shake one key aspect enough
sampl satisfi increas capac brought on-lin
technolog improv new instrument recent
novaseq attempt settl issu built incred
detail sampl capac vs demand model major end
market research nipt dtc cancer popseq
key take-away analys enough
capac satisfi potenti sampl demand market
thu modifi famou quot chief brodi jaw
go need bigger boat put lightli sequenc environ
go need much bigger sequenc mani
hit sampl inflect next two year nipt dtc
popseq clinic sequenc take
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
key tidbit model analys
current estim instal base novaseq nextseq
miseq respect market run sampl
suppli shortag sampl grow exponenti time
get number state model detail
end market variou assumpt estim
mm sampl run major come nipt dtc
much lower asp
satisfi sampl demand calcul compani need place
signific number new box bring total instal base number
nova nextseq miseq even capac per box
increas materi stagger number would less box
would replac cycl
mean potenti revenu opportun needless
say increment revenu potenti massiv
base placement need price degrad
estim potenti increment bn instrument revenu
realist believ number much lower closer
bn rang given improv throughput would still impli
instrument revenu per annum vs current level instrument
look consum potenti associ sampl run major
market estim could see bn addit rev
realist base current consum revenu today vs revenu potenti
would surpris see pull increment bn
consum per annum penetr share vs
mean stock
given analysi consist competit environ
believ could put low upper teen growth
current price estim share bake long-term growth
assumpt get valu growth low ebtida
adjust model get target revenu vs
prior pt move equat upsid current
given highli sensit natur work offer model
ask nice
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin may et
analyst ross muken luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
